Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
⁃ Uncommon EGFR Mutant Advanced NSCLC
Locations
Other Locations
China
Yongchang Zhang
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Nong Yang, MD
yangnong0217@163.com
+8613055193557
Time Frame
Start Date: 2020-03-24
Estimated Completion Date: 2027-12-24
Participants
Target number of participants: 800
Treatments
Cohort 1 Uncommon EGFR exon 19del
patients with uncommon EGFR exon 19del
Cohort 2 EGFR exon 19delins
patients with EGFR exon 19delins
Cohort 3 EGFR exon 18del
patients with EGFR exon 18del
Cohort 4 Common Uncommon Point Mutations
patients with common uncommon point mutations
Cohort 5 Rare Uncommon Point Mutations
patients with rare uncommon point mutations
Cohort 6 Compound Mutations Uncommon With Uncommon
patients with compound mutations uncommon with uncommon
Cohort 7 Compound Mutations Uncommon With Common
patients with compound mutations uncommon with common
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital